Chronic obstructive pulmonary disease (COPD) evidentiary framework

OHTAC COPD Collaborative
Record ID 32012000625
English
Authors' objectives: The objective of this report series is to create an evidentiary base and economic analysis that will guide investment in the treatment of chronic obstructive pulmonary disease (COPD) in a way that optimizes patient outcomes and system efficiencies. This evidentiary platform concerning the effectiveness and cost-effectiveness of treatment strategies for patients with COPD will be used to build a provincial COPD strategy.
Authors' recommendations: - A significant proportion of COPD patients were willing to forgo a potentially life-saving intervention, particularly when it was framed as an indefinite procedure. - COPD patients who were willing to forgo either IMV or NPPV could not be reliably predicted by known covariates (such as age, quality of life). - COPD patient preferences for ventilation were not stable, but varied depending on how the intervention was described. Many COPD patients also altered their preferences when asked to consider ventilation under different hypothetical health states. - A systematic review of the patient preference literature offers many insights. However, the process is time-consuming due to the heterogeneity of study designs, outcomes measures, and terminology.
Details
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Evidence-Based Practice
  • Evidence-Based Medicine
Contact
Organisation Name: Medical Advisory Secretariat
Contact Address: Medical Advisory Secretariat, 20 Dundas Street West, 10th Floor, Toronto, ON M5G 2N6 CANADA. Tel: 416-314-1092l; Fax: 416-325-2364;
Contact Name: MASinfo.moh@ontario.ca
Contact Email: MASinfo.moh@ontario.ca
Copyright: Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care (MAS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.